A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)

By afschroeder • June 8, 2025

Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC; University of California Hematologic Malignancies Consortium. A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leuk Res. 2025 Jun 2;155:107717. doi: 10.1016/j.leukres.2025.107717. Epub ahead of print. PMID: 40479857.

Tags: Azacitidine, Hematology/Oncology, Ibrutinib, Myelodysplastic syndromes, Publications

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li[...]

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E,[...]

An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapies

Ishihara J, Lee JK, Priceman SJ. An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapies. Mol Ther. 2025 Dec 23:S1525-0016(25)01041-X. doi:[...]